Sangamo jumps on ZFP deal with Shire

Sangamo BioSciences Inc. (NASDAQ:SGMO) gained $0.74 (21%) to $4.19 on Wednesday after granting Shire plc (LSE:SHP; NASDAQ:SHPGY) exclusive, worldwide rights to zinc finger DNA-binding protein (ZFP) therapeutics targeting four genes -- Factors VII, VIII, IX and X. Shire plans to develop the therapeutics for hemophilia A and B. Shire also has rights to designate three additional gene targets. ...